EA
PDLI

Emerald Acquisition’s PDL BioPharma, Inc. PDLI Stock Holding History

Emerald Acquisition’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$7.32M Sell
2,183,919
-824,522
-27% -$2.62M 0.01% 1006
2016
Q2 		$9.45M Buy
+3,008,441
New +$10M 0.02% 962

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerald Acquisition's PDLI Position: Q3 2016 in Review

Emerald Acquisition reduced its PDL BioPharma, Inc. (PDLI) stake by 27% in Q3 2016, selling an estimated $2.62M and leaving 2,183,919 shares worth $7.32M. The position accounts for 0.01% of the portfolio, ranked #1006.

Emerald Acquisition first reported a position in PDLI in Q2 2016 and has held it in 2 quarters since. The position peaked at $9.45M in Q2 2016. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Emerald Acquisition held 2,183,919 shares of PDL BioPharma, Inc. worth $7.32M as of Q3 2016.
  • Emerald Acquisition sold 824,522 PDL BioPharma, Inc. shares in Q3 2016, an estimated $2.62M.
  • PDL BioPharma, Inc. made up 0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1006 holding.
  • Emerald Acquisition first reported a position in PDL BioPharma, Inc. in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's PDL BioPharma, Inc. position peaked at $9.45M in Q2 2016.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.